Havana, 6 Nov (RHC) The drug Itolizumab, monoclonal antibody developed by the Center of Molecular Immunology (CIM), in collaboration with the Indian company Biocon, received the authorization to start the phase III of the clinical trial in patients with COVID-19 in the United States, Mexico and Brazil, this Cuban scientific institution refers in its Twitter social network account.
In 2014, it was awarded one of the national prizes of the Cuban Academy of Sciences, and since April, this humanized monoclonal antibody is part of the medical care protocol for COVID-19 in Cuba.
Itolizumab is a molecule developed in the CIM for the treatment of lymphomas and leukemias, and it is able to block the proliferation and activation of T-lymphocytes, behaving as an immunomodulator.
With this drug, 60% of severe and critical patients recover respiratory function and survive the severity, reports the website of BioCubaFarma. The CIM is a closed-cycle biotechnology institution that, from the culture of superior cells, directs its basic research, development and manufacture of products, to the treatment of cancer and other autoimmune diseases.
(Taken from RHC)